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Effects of 5'-N-ethylcarboxamideadenosine (NECA) on erythropoietin
production. The present studies were undertaken to assess the effects of
5'-N-ethylcarboxamideadenosine (NECA), an adenosine analogue, on
erythropoietin (Epo) production. NECA (0.05 and 0.1 mol/kg i.v.)
produced significant increases in serum Epo levels (368.8 56.1 and
384.6 45,9 mU/mI, respectively) in exhypoxic polycythemic mice
after a four hour exposure to hypoxia when compared with hypoxia
controls (133.2 18.2 mU/mi). The hypoxic kidney Epo levels were
46.4 13,4 mU/kg kidney which were significantly higher than nor-
moxic kidney Ep levels (<1.24 mU/kg kidney). Theophylline (20 mg/kg
i.p.), an adenosine receptor antagonist, significantly inhibited the stim-
ulatory effects of NECA on serum Epo levels. In vitro cultures of an
Epo producing hepatoceilular carcinoma (Hep3B) cell line with NECA
( 10—6 M) for 20 hours under hypoxic conditions (1% 02) produced
significant increases in medium levels of Epo when compared with
hypoxia controls. Hepatocellular carcinoma cells treated with NECA at
a concentration range of iO M to 5 x l0 M for one hour in a hypoxic
atmosphere also had significantly higher cAMP levels than that of
hypoxia controls. Scatchard analyses of F3HINECA binding to mem-
brarle preparations of hepatocellular carcinoma cells showed low affiñ-
ity binding sites with a dissociation-constant (Kd) of 0.44 /M and a
binding capacity of 863 fmol/mg protein. These findings suggest that the
increase in Epo production in response to NECA under hypoxic
conditions can be attributed, at least in part, to stimulation of adenosine
A2 receptors which is coupled to adenylyl cyclase activation.
Erythropoietin (Epo) is a glycoprotein produced primarily by
the adult kidney [1—3] and by the liver of the fetus [41 and
anephric adult animal [51, which causes an increase in the
proliferation and differentiation of erythroid progenitor cells in
the bone marrow. Hypoxia is not only a stimulus for Epo
secretion [6] but has also been reported to enhance adenosine
production [7], Adenosine is a nucleoside which is involved in
the regulation of a number of biological processes [8—15]. We
have recently reported that adenosine and NECA, an adenosine
analogue with A2 receptor agonist properties, affect radioiron
incorporation in red blood cells of exhypoxic polycythemic
mice (EHPCM) exposed to hypoxia [16]. However, the mea-
surement of radioiron incorporation in red blood cells cannot
completely exclude the possibility of an interaction of ade-
nosine on the response of bone marrow cells to Epo. The
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purpose of the present studies is to assess the direct effects of
NECA on Epo production. Firstly, in vivo experiments were
carried out to investigate the effects of NECA on Epo produc-
tion in EHPCM, using a highly sensitive radioimmunoassay
(RIA) for Epo in the mouse which we have developed in recent
years [17—19]. Secondly, in vitro studies, using a cloned Epo
producing hepatocellular carcinoma cell line (Hep3B), were
performed to elucidate the mechanism of the direct effect of
NECA on Epo production and to clarify adenosine A2 receptor
involvement in the regulation of Epo production.
Methods
In vivo Epo studies
Exhypoxic polycythemic mice (EHPCM) were employed to
determine the in vivo effects of NECA on Epo production. The
details of the method used in these studies have been previously
described elsewhere [6, 19]. Briefly, CD-i strain female mice
(Charles River Breeding Laboratories, Wilmington, Massachu-
setts, USA) were exposed to hypoxia in a hypobaric chamber at
0.42 atm for 22 hours daily for two weeks. On posthypoxic days
3, 4, 5, and 6, 5'-N-ethylcarboxamideadenosine (NECA) i.v.,
8-bromo-cyclic AMP (8bcAMP) i.v., and theophylline i.p. (all
agents were obtained from Sigma Chemical Co., St. Louis,
Missouri, USA) were administered as single doses in a volume
of 0.2 ml. The mice were exposed to reduced atmospheric
pressure (0.42 atm) in a hypoxic chamber for four hours
immediately after the last injection on the sixth posthypoxic day
and then weighed, anesthetized with ether and exsanguinated
via cardiac puncture. Blood was removed for the determination
of microhematocrit and serum Epo concentration. Blood sam-
ples used for the Epo assay were allowed to clot at 4°C and after
centrifugation the serum was removed and stored at —70°C until
assayed for Epo. Kidneys and livers were also removed,
weighed, and frozen at —70°C prior to the determinations of
tissue Epo levels. Kidney and liver were extracted for Epo
determination by a modification of a method which has been
reported previously [201. In short, tissues were suspended in
PBS (1 ml/200 mg kidney) containing 0.1 mM phenylmethylsul-
fonyl fluoride and 1 rM phosphoramidon (Sigma Chemical Co.)
and then homogenized using a polytron homogenizer and
centrifuged at 12,000 x g for 30 minutes at 4°C. The supernatant
was removed and stored at —70°C prior to Epo assay. The
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multiple range test of Duncan [21] was used for the comparison
of the several in vivo treatment groups with vehicle controls.
In vitro Epo studies
A human hepatocellular carcinoma cell line (Hep3B) [22, 23]
was employed to determine the in vitro effects of NECA on Epo
production and cAMP accumulation. Hep3B cells were carried
in a monolayer cell culture and maintained in 75 cm2 Corning
culture flasks containing Eagle's minimal essential medium
(MEM) supplemented with 10% fetal bovine serum (PBS), 0.1
m nonessential amino acids, 1 m sodium pyruvate, 100 U/ml
penicillin G, and 100 g/ml streptomycin in a humidified atmo-
sphere of 5% C02/95% air at 37°C. The culture medium was
replaced every two days. Cells were detached with trypsin and
aliquots of 2.5 x i05 viable cells (determined by trypan blue dye
exclusion) were transferred to 24 multi-well plates. Each exper-
iment was carried out with low density cells before they
reached confluency. The cells were incubated with NECA in
concentrations of iO M to 5 x l0 M in the presence of 1
U/ml adenosine deaminase (ADA, Sigma) under hypoxic con-
ditions (1% 02, 5% C02, and 94% N2) for 20 hours following 24
hour preincubation in a normoxic atmosphere. The details of
the hypoxic conditions used in the present studies have been
described previously [24]. At the end of the incubation period,
the supernatant was harvested and frozen at —70°C prior to Epo
RIA. The multiple-range test of Duncan [21] was used for the
comparison of the several in vitro treatment groups compared
with controls.
Epo radioimmunoassay. The Epo activity was determined
with a sensitive RIA. The details of the RIA procedure used in
our laboratory have been reported previously [17, 18]. Purified
human recombinant Epo was used in a range of 3.125 to 400
mU/ml for the preparation of the human Epo standard curve.
Mouse Epo with a specific activity of 4.0 U/mg protein pro-
duced by murine erythroleukemia cells (Hyclone Labs, Logun,
Utah, USA) was used in a range of 6.25 to 1600 mU/ml for the
preparation of the mouse Epo standard curve [19].
cAMP studies in vitro. The determination of cAMP was
performed according to a modification of the procedure de-
scribed by Ueno et al [24]. Hep3B cells in 24 multi-well plates
were incubated in 0.5 ml of serum-free medium with NECA at
a concentration range of i0 M to 5 x jQ5 M in the presence
of I U/ml ADA for one hour in a hypoxic atmosphere following
24 hours preincubation in a normoxic atmosphere. The incuba-
tion was terminated by adding 0.5 ml of ice-cold 12% trichlo-
roacetic acid (TCA) at 4°C. The medium was removed and the
cells were washed again with an additional 0.5 ml of 6% TCA.
The samples were centrifuged at 3000 rpm at 4°C for 30 minutes
and TCA was extracted from the supernatant four times with 5
volume water-saturated ether. The remaining ether was evapo-
rated by warming, and the supernatant was lyophilized. The
dried samples were resuspended in sodium acetate buffer,
appropriately diluted and assayed for cAMP by RIA using a
cAMP assay kit from DuPont-New England Nuclear (Boston,
Massachusetts, USA).
[3HJNECA binding studies. Hep3B cells were rinsed with
PBS and harvested in 50 mrvi Tris-HC1, pH 7.4, using a rubber
policeman. The cell suspension was homogenized for 30 sec-
onds using a polytron homogenizer at 5°C and centrifuged at
40,000 x g for 30 minutes in a refrigerated centrifuge. The
supernatant was discarded and the resulting pellet was resus-
pended in the same buffer with a polytron homogenizer and
recentrifuged at the same gravity. This procedure was repeated
twice. At the end of the second centrifugation, the pellet was
resuspended in Tris buffer and incubated for 30 minutes at 25°C
in the presence of 1.0 U/ml adenosine deaminase to remove
endogenous adenosine. After incubation, the suspension was
centrifuged at 40,000 x g for 30 minutes at 4°C. The resulting
pellet was resuspended in Tris buffer and the protein concen-
tration was adjusted to 200 sg/ml using a protein assay kit
(Bio-Rad).
Binding of [3HINECA to the particulate fraction of Hep3B
cells was carried out according to the method previously
reported [10, 25] with minor modifications. Briefly, duplicate
samples of membrane preparation (225 g) were incubated with
more than 10 different concentrations of [3H]NECA, 50 nM
CPA (to eliminate A1 receptor binding) [25], 1 U/ml of ade-
nosine deaminase in the presence or absence of 100 M unla-
beled NECA for 120 minutes at 25°C in a final volume of 200 jl.
Incubations were terminated by rapid filtration through What-
man GF/C glass fiber filter (Whatman, Clifton, New Jersey,
USA) under reduced pressure. Filtration and washing required
a total time of less than 10 seconds. The filters were placed in
scintillation vials with scintillation fluid and the vials were left
overnight and counted with a liquid scintillation counter. Spe-
cific binding of [3H]NECA was defined as the difference of the
amount of [3H]NECA bound in the absence and the presence of
an excess of 100 M of unlabeled NECA. The data obtained
from our binding studies were subjected to computerized anal-
ysis by using the ligand program [26]. The multiple range test of
Duncan [21] was used for the comparison of data in several
groups and P < 0.05 was regarded as being statistically signif-
icant.
Results
Serum levels of Epo in EHPCM treated with NECA in
concentrations of 0.05 and 0.1 mol/kg and exposed to four
hour hypoxia were significantly increased to 368.1 56.1 (N =
14) and 384.6 45.9 mU/ml (N = 22), respectively, when
compared to vehicle controls (133.2 18.2 mU/mi, N = 22)
(Table 1). Epo levels in kidney extracts were measured in some
experiments (Table 2). Kidney Epo levels in EHPCM exposed
to four hour hypoxia showed 46.4 13.4 mU/kg kidney (N =
22), whereas Epo levels in normoxic EHPCM kidneys were
undetectable (<1.24 mU/g kidney, N = 10). NECA at doses of
0.05 and 0.1 prnol/kg in combination with four hour hypoxia
produced significantly increased kidney levels of Epo (0.05
/Lmol/kg, 196.1 38.8 mU/g kidney, N = 14; 0.1 jmol/kg, 188.1
48.6 mU/g kidney, N = 16), although Epo levels in liver
extracts were below detectable levels (<1.24 mU/g liver).
However, NECA produced much less of an increase in serum
levels and kidney levels of Epo at a dosage of 0.02 pmol/kg
(serum Epo, 218.9 34.5 rn/mI; kidney Epo, 116.0 45.1
mU/kg kidney) and 0.2 moI1kg (serum Epo, 281.8 69.4
mU/ml; kidney Epo, 93.6 44.3 mU/g kidney) than those seen
at 0.05 and 0.1 prnol/kg. In addition, NECA produced sedative
effects in all mice and was lethal when administered in concen-
trations higher than 0.5 smol/kg, as previously reported [16].
Theophylline (20 mg/kg i.p.) significantly inhibited the stim-
ulatory effects of NECA on serum Epo levels (N = 17—19),
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Table 1. Effects of NECA on serum Epo levels in exhypoxic polycythemic mice in response to four hour hypoxia on the sixth posthypoxic
day
NECA p,nol/kg
0 0.02 0.05 0.1 0.2 0.5
Serum Epo 133.2 18.2 218.9 34.5 368.8 45,9a 384.6 69.4a 281.8 69.4 115.6 35,4
mU/mi N=22 N=18 N=14 N=22 N=6 N=7
NECA at a dose range of 0.02 to 0.5 mol/kg/day was administered via the tail vein in a single dose in a 0.2 ml volume on posthypoxic days 3,
4, 5, and 6. Each value represents the mean SEM.
a Significantly different from control (P < 0.05)
Table 2. Effects of NECA on kidney Epo levels in exhypoxic polycythemic mice in response to four hour hypoxia on the sixth posthypoxic
day
NECA pmol/kg
0 0.02 0.05 0.1 0.2
Kidney Epo 46.2 13.2 116.0 45.1 196.1 38.8a 118.1 48,6a 93.6 44.3
mUIg N= 22 Nl2 N'14 N16 N=6
NECA at a dose range of 0.02 to 0.2 mol/kg/day was administered via the tail vein on posthypoxic days 3, 4, 5, and 6. Each value represents
the mean SEM.
a Significantly different from control (P < 0.05)
whereas theophylline alone did not produce a significant effect
on serum Epo levels (Fig. 1). Moreover, 8bcAMP (0.2 ml of 6
.tM i.v.) produced a significant increase in serum Epo levels
(384.2 6.4 mU/ml) when compared to vehicle controls (144.2
34.0 mU/ml, N = 11) (Fig. 2). Throughout the present studies
no significant changes were found in mean kidney weight, body
weight or hematocrit values of any of the mice studied.
When the Hep3B cells were incubated at early confluency
under hypoxic conditions (1% 02, 5% C02, 94% N2), the
medium levels of Epo were exponentially increased over a
period of 16 to 24 hours in a time dependent manner (data not
shown). In the present study we have investigated the effects of
NECA on Epo secretion in Hep3B cells in response to hypoxia.
In vitro cultures of Hep3B cells with NECA in concentrations
of 106 M, iO M, and 5 x 10-s M in the presence of I U/ml
ADA for 20 hours under hypoxic conditions produced a signif-
icant dose-dependent increase in Epo levels in the medium
(34.38 0.77 mU/ml, 36.15 1.32 mU/mi, respectively) when
compared with hypoxia controls (30.69 0.72 mU/mi) (Fig. 3).
When Hep3B cells were treated with NECA in the presence of
1 U/mI ADA for one hour under hypoxic conditions, cAMP
levels were significantly enhanced in a dose-dependent manner
in a concentration range of i0— M to 5 X io— M with an ED50
of 0.31 M calculated by non-linear least square curve fitting
(Fig. 4). We have also evaluated the time course of medium
levels of Epo in Hep3B cell cultures treated with 8bcAMP in a
hypoxic atmosphere. Medium Epo levels after six hours incu-
bation are less than 10% of those seen at 20 hours. Epo levels
increased in a time-dependent manner (data not shown). In
13H]NECA binding studies to Hep3B membrane preparations
specific binding reached a plateau around 60 minutes and
remained constant at least for two hours (Fig. 5). Nonspecific
binding of [3HINECA was 53% of total binding at a [3H]NECA
concentration of 0.1 /.LM. In addition, a linear relationship (r =
0.854) was found between specific binding of [3H]NECA and
protein concentration (data not shown). As shown in Figure 6,
the binding studies suggested that Hep3B cells contained a
single class of binding site with a dissociation constant (Kd) of
0.44 /LM and maximal binding capacity (Bmax) of 863 fmol/mg
protein (N = 5).
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Fig. 1. Effects of theophylline on NECA enhancement of serum Epa
levels in exhypoxic polycythemic mice in response to four hour hypoxia
on the sixth posthypoxic day. NECA (0.1 smol/kg/day i.v.; N = 17),
theophylline (20 mg/kg/day i.p.; N = 19), and NECA plus theophylline(N = 19) were administered on posthypoxic days 3, 4, 5, and 6. Each
value represents the mean SEM and the asterisk (*) indicates
significantly (P < 0.05) different from control (N 18). ** indicates
significantly different from NECA alone (P < 0.05).
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Fig. 2. Effects of 8bcAMP on serum Epo levels in exhypoxic polycy-
themic mice in response to four hour hypoxia on the sixth post hypoxic
day. 8bcAMP (N = 10) in a dosage of 6 tM/kg/day was administered via
the tail vein on posthypoxic days 3, 4, 5, and 6. Each value represents
the mean SCM and the asterisk (*) indicates significantly (P < 0.05)
different from control (N = 11).
Discussion
The number of proposed biologic roles for adenosine has
increased considerably in recent years. Two subclasses of cell
membrane adenosine receptors have been proposed [9]. A1
adenosine receptors exhibit high affinity in binding studies and
are coupled to and inhibit adenylyl cyclase. On the other hand,
A2 adenosine receptors exhibit lower affinity and are coupled to
stimulation of adenylyl cyclase. In addition, adenylyl cyclase
studies have revealed a third adenosine-sensitive site, namely
the P-site [27]. This is not a receptor but rather an intracellular
binding site, which is postulated to be involved in the inhibition
of adenylyl cyclase [28].
Catabolism of adenosine is brought about primarily by two
enzymes, adenosine deaminase and adenosine kinase. Ade-
nosine deaminase converts adenosine to inosine, which is an
inactive metabolite, and adenosine kinase converts adenosine
to 5'-AMP. NECA is believed to be less sensitive to metabolism
by adenosine deaminase [9, 29] and is not a substrate for
adenosine kinase [9]. In addition, adenosine is transported into
cells by a high affinity uptake system which removes it from the
extracellular compartment [9]; it has also been reported that
NECA is not a good substrate for the adenosine uptake system
[30]. For this reason, we selected NECA for our studies
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Fig. 3. Effects of NECA on Epo secretion in Hep3B cells exposed to
hypoxia. Hep3B cells were incubated with NECA at a concentration
range of lO M to 5 x lO M for 20 hours under hypoxic (1% 02)
conditions. Each value represents the mean SEM of 12 samples and
the asterisk (*) indicates significantly different from hypoxia control (P
<0.05).
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Fig. 4. Effects of NECA on cAMP accumulation in Hep3B cells
exposed to hypoxia. Hep3B cells were incubated with NECA in a
concentration range of i0 M to 5 >< l0— M for 60 minutes under
hypoxic conditions. Each value represents the mean SCM of eight
samples and the asterisk (*) indicates significantly different from
hypoxia control (P <0.05).
because it is a potent A2 receptor agonist [11] and is more stable
than adenosine itself.
In the present studies, we have designed an in vivo model
using EHPCM to assess the effects of NECA on Epo produc-
tion, since we have developed an RIA for mouse Epo in recent
years [19]. NECA produced significant increases in serum Epo
levels in EHPCM in response to hypoxia in a dose range of 0.05
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Incubation time, minutes
Fig. 5. Time-course of total ( U), specj/Ic (S 5) and non-
specific (O—Q) binding of [3HJNECA to Hep3B cell membranes.
Hep3B cell membrane preparations were incubated with 100 nM [3H]N-
ECA, 50 nM CPA and 1 U/mI of adenosine deaminase in the presence or
absence of 100 LM unlabeled NECA for the indicated periods of time at
25°C. Specific binding is defined as the difference between total and
nonspecific binding.
to 0.1 mol/kg. There were no significant changes in the
hematocrits of EHPCM at these doses, suggesting that the
enhancement of serum Epo levels induced by this adenosine
agonist was not associated with a change in hematocrit. How-
ever, NECA produced much less of an increase in serum and
kidney levels of Epo in a dosage of 0.2 tmol/kg than those seen
at 0.05 and 0.1 tmo1/kg and appeared to be sedative and lethal
when administered in concentrations higher than 0.5 jimollkg,
as previously reported [161. Therefore, the decrease in serum
Epo levels at higher concentrations of NECA may be attributed
to its toxicity in vivo. In parallel with the increase in serum
levels of Epo, NECA at the same concentrations produced
significant increases in Epo levels in kidney extracts. Epo levels
were nondetectable in the liver extracts. This finding suggests
that contamination of extracts with Epo contained in trapped
blood in tissues does not contribute to the Epo levels in the
tissue extracts.
Theophylline, which is an adenosine receptor antagonist [31,
321, inhibited the stimulatory effects of NECA on serum Epo
levels in EHPCM in response to hypoxia, whereas theophylline
alone did not produce a significant effect on serum levels of
Epo. These findings firmly suggest that NECA is capable of
stimulating Epo production through adenosine membrane re-
ceptors, which stimulate adenylyl cyclase resulting in an in-
crease in the generation of cAMP. In contrast, it is less likely
that the inhibitory P-site may be involved in NECA-induced
enhancement of serum Epo levels, because NECA has been
reported to be virtually inactive at P-sites, and partly because
theophylline has been postulated to have no antagonistic effect
at P-sites [28]. In support of this hypothesis, 8bcAMP also
significantly enhanced serum levels of Epo in response to
hypoxia. It has also been reported that adenosine caused a
significant increase in Epo production in an isolated rat kidney
perfused with medium gased with 5% oxygen [33]. However, an
effect of adenosine agonists on renal hemodynamics [13] or an
increase in other humoral factors which could possibly account
Fig. 6. ['HJNECA binding to Hep3B cell membranes. Binding [3H1
NECA was measured as described in the Materials and Methods
section. The Scatchard plots generated from the specific binding data by
means of the LIGAND program are shown in this figure, Each value
represents the mean of three to five different experiments. Inset:
[3H}NECA binding to Hep3B cell membranes.
for the changes in Epo production in response to hypoxia
cannot be completely excluded. Therefore, our in vitro studies
using an Epo producing Hep3B cell line were designed to assess
the direct effects of NECA on Epo production, and moreover,
to elucidate the mechanism of this effect. Since NECA failed to
significantly stimulate Epo production in a normoxic atmo-
sphere, we selected a hypoxia model for the evaluation of the
effects of NECA on Epo production as discussed previously
[34, 35], NECA at a concentration range of 10—6 M to 5 X l0
M produced a significant dose-dependent increase in Epo secre-
tion in Hep3B cells incubated for 20 hours under hypoxic
conditions. Likewise, in vitro cultures of Hep3B cells with
NECA in concentrations of l0 M to 5 X l0 M for one hour
in a hypoxic atmosphere caused a significant dose-dependent
increase in cAMP levels in Hep3B cells. We have recently
reported the effects of N6-cyclohexyladenosine (CHA) on Epo
production in our Hep3B cell system [34]. CHA produced
significant increases in cAMP and Epo production in a concen-
tration range of i05 to 5 x 1O M, whereas no significant
change was seen at a dose range below 106 M. CHA is
generally considered to be more potent at A4 receptors than
NECA. As we expected, the ED5n of CHA for cAMP accumu-
lation in Hep3B cells was 8.11 ILM, which is higher than that of
NECA (0.31 jiM), suggesting that NECA is more potent than
CHA on cAMP and Epo production in HepB cells. In support of
the involvement of cAMP in the stimulatory effects of NECA
on Epo production in our Hep3B cells, 8bcAMP at a concen-
tration range of l0 to l0 M and forskolin at a concentration
range of 1.6 x 10 M to 4 x 10 M produced a significant
increase in Epo secretion by Hep3B cells in response to
hypoxia [35].
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In the present studies, we have characterized A2 receptors in
Hep3B cells using NECA. In recent years, considerable im-
provement has been achieved in binding assays for A2 receptors
using [3H]NECA [10, 15, 251. The A1 component of the binding
was reported to be eliminated specifically by using N-ethyl-
maleimide [15] or CPA [25]. Bruns et al (1986) have demon-
strated that in the presence of 50 flM CPA, 98% of the A2
receptor binding of [3HINECA, are displaced. In the present
studies, less than 6% of the [3H]NECA binding to Hep3B
membrane preparations were displaced by the presence of 50
flM CPA. In our binding assay, 53% of the total binding was
nonspecific at a [3H]NECA concentration of 100 n. Since the
Kd value for [3H]NECA binding is relatively high, as reported
previously [8], it seems likely that the percent nonspecific
binding is relatively high at high concentrations of the ligand.
The Scatchard plot of the [3HINECA binding data resulted in a
straight line and the ligand program revealed a single-site fit
rather than a two-site fit, suggesting that sensitive binding sites
for NECA with a dissociation constant (Kd) of 0.44 M are
present in our Hep3B cells in culture. Bruns et al [251 have
reported a Kd value of 3.5 n for a high affinity A2 site and 35
n for a low affinity A2 site in rat brain striatal membranes [25].
On the other hand, it has been reported that the binding of
[3H]NECA to neutrophils supports the presence of an ade-
nosine A2 receptor on these cells with a Kd value of 0.22 /.M [8],
and the concentration required for binding and for a biological
effect (inhibition of superoxide anion generation) in neutrophils
correlated very well. This value is the same order of magnitude
as the Kd value for our Hep3B cells. Bruns et at [25] have
reported that rat brain striatal membranes possess at least two
A2 receptors, which could be due to the mixed cell population
of their brain cell preparation. Williams et a! [14] reported a
single class of A2 receptors in their PC 12 cell line. In the present
studies, the ED50 for NECA-stimulated cAMP accumulation in
our Hep3B cells was 3.1 x l0— M (calculated by non-linear
least square curve fitting), which is consistent with the dissoci-
ation constant (Kd) of NECA (4.4 x 10 M). These findings
indicate that NECA generates cAMP through adenosine A2
receptors coupled to adenylyl cyclase. It is possible that there is
a lag in the time course between the effects of NECA on the
adenosine receptor coupling to adenylyl cyclase and the cas-
cade of intracellular events which lead to an increase in Epo
production at a later time following the increase in cAMP.
There may be several steps that follow the increase in cAMP
before Epo is actually secreted [36]. Therefore, the NECA
dose-response curve for Epo production in Hep3B cells is
similar to, but may not necessarily be the same as that of
cAMP.
In conclusion, the present studies indicate that Epo produc-
tion is regulated by adenosine membrane A2 receptors which
are coupled to activation of adenylyl cyclase and the generation
of intracellular cAMP in the presence of hypoxia.
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